公开(公告)号：US20240226178A1

公开(公告)日：2024-07-11

申请号：US18558689

申请日：2022-05-03

Applicant: UNIVERSITY OF WASHINGTON

Inventor： Charles E. MURRY ,  Silvia MARCHIANO ,  Hans REINECKE ,  Alessandro BERTERO

IPC: A61K35/34 ,  A61K31/343 ,  A61K31/55 ,  A61K47/46 ,  A61L27/36 ,  A61L27/38 ,  A61P9/06 ,  C12N5/077 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90

CPC classification number: A61K35/34 ,  A61K31/343 ,  A61K31/55 ,  A61K47/46 ,  A61L27/3633 ,  A61L27/3826 ,  A61L27/3895 ,  A61P9/06 ,  C12N5/0657 ,  C12N9/22 ,  C12N15/11 ,  C12N15/907 ,  C12N2310/20 ,  C12N2506/02 ,  C12N2800/80

Abstract: Described herein are compositions and methods related to the treatment of a cardiovascular disease or disorder. Also described herein are cells, stem cells (including embryonic and pluripotent stem cells), and in vitro-differentiated human cardiomyocytes in which HCN4 (HCN4), Cav3.2 (CACNA1H) and NCX1 (SLC8A1) activities are at least partially inhibited, and Kir2.1 (KCNJ2) activity is at least partially stimulated in such cells. Also described herein are formulations for the delivery of such cells and methods of transplanting cardiomyocytes, e.g., for the treatment or prevention of a disease or disorder.